Biotechnology giant CSL has confirmed it will shelve development of the University of Queensland coronavirus vaccine after participants in the phase 1 trial returned false-positive HIV test results.

As reported by this masthead on Friday, a billion-dollar deal made by the Morrison government for the 51 million doses of the vaccine and CSL will abandon further clinical trials of the product, known as v451.

CSL's biotechnology manufacturing facilities in Melbourne, where the University of Queensland vaccine was set to be manufactured should it be successful.

CSL’s biotechnology manufacturing facilities in Melbourne, where the University of Queensland vaccine was set to be manufactured should it be successful.

In a statement to the ASX this morning, the $137 billion blood plasma giant said that while the vaccine candidate was safe, data from the phase 1 study lead to the conclusion that “significant changes would be needed to HIV testing procedures in the healthcare setting to accommodate the rollout of this vaccine.”

The University of Queensland commenced its phase 1 study of the vaccine, using what is known as “molecular clamp” technology, in July.



Source link

Categories: Daily Updates

0 Comments

Leave a Reply

Your email address will not be published. Required fields are marked *